Literature DB >> 14760158

Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis.

J Texereau1, S Marullo, D Hubert, J Coste, D J Dusser, J Dall'Ava-Santucci, A T Dinh-Xuan.   

Abstract

BACKGROUND: The severity of lung disease varies widely in patients with cystic fibrosis (CF) who have the same type of mutations of the cystic fibrosis transmembrane regulator (CFTR) gene, suggesting involvement of "modifier" genes. The nitric oxide synthase 1 (NOS1) gene is a candidate for this role because exhaled nitric oxide (NO) is reduced in patients with CF and NOS1 activity contributes to transepithelial ionic transport, immune defence, and non-specific inflammation of the airways.
METHODS: Dinucleotide GT repeat polymorphism was studied in the 5' untranslated region of the NOS1 gene, immediately upstream from the transcription initiation site, in 59 patients with CF and 59 healthy controls.
RESULTS: Nineteen alleles of the NOS1 gene were identified according to the number of GT repeats (from 18 to 36) in the 5 untranslated region. Exhaled NO levels were significantly correlated with the number of GT repeats. Patients with CF who had the NOS1 genotype associated with high NO production had a slower decline in lung function during the 5 year follow up period. There was no confounding effect of age, chronic bacterial colonisation of the airway, or CFTR genotype.
CONCLUSIONS: These data suggest a possible link between the NOS1 gene locus and the rate of decline in lung function in patients with CF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14760158      PMCID: PMC1746921          DOI: 10.1136/thorax.2003.006718

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  10 in total

1.  Differential and constitutive expression of neuronal, inducible, and endothelial nitric oxide synthase mRNAs and proteins in pathologically normal human tissues.

Authors:  C S Park; G Krishna; M S Ahn; J H Kang; W G Chung; D J Kim; H K Hwang; J N Lee; S G Paik; Y N Cha
Journal:  Nitric Oxide       Date:  2000-10       Impact factor: 4.427

Review 2.  Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force.

Authors:  S Kharitonov; K Alving; P J Barnes
Journal:  Eur Respir J       Date:  1997-07       Impact factor: 16.671

Review 3.  Genotype and phenotype in cystic fibrosis.

Authors:  J Zielenski
Journal:  Respiration       Date:  2000       Impact factor: 3.580

Review 4.  Phagocyte oxidants and nitric oxide in cystic fibrosis: new therapeutic targets?

Authors:  A van der Vliet; C E Cross
Journal:  Curr Opin Pulm Med       Date:  2000-11       Impact factor: 3.155

5.  Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene.

Authors:  H Grasemann; N Knauer; R Büscher; K Hübner; J M Drazen; F Ratjen
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

6.  Exhaled nitric oxide in patients with asthma: association with NOS1 genotype.

Authors:  M E Wechsler; H Grasemann; A Deykin; E K Silverman; C N Yandava; E Israel; M Wand; J M Drazen
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

7.  Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype.

Authors:  S R Thomas; S A Kharitonov; S F Scott; M E Hodson; P J Barnes
Journal:  Chest       Date:  2000-04       Impact factor: 9.410

8.  RNA diversity has profound effects on the translation of neuronal nitric oxide synthase.

Authors:  Y Wang; D C Newton; G B Robb; C L Kau; T L Miller; A H Cheung; A V Hall; S VanDamme; J N Wilcox; P A Marsden
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

Review 9.  Multiple roles of nitric oxide in the airways.

Authors:  F L M Ricciardolo
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

10.  Reduction of neuronal and inducible nitric oxide synthase gene expression in patients with cystic fibrosis.

Authors:  Jörg Dötsch; Jan Puls; Thorsten Klimek; Wolfgang Rascher
Journal:  Eur Arch Otorhinolaryngol       Date:  2002-04       Impact factor: 2.503

  10 in total
  14 in total

1.  Exon skipping through the creation of a putative exonic splicing silencer as a consequence of the cystic fibrosis mutation R553X.

Authors:  Isabel Aznarez; Julian Zielenski; Johanna M Rommens; Benjamin J Blencowe; Lap-Chee Tsui
Journal:  J Med Genet       Date:  2007-05       Impact factor: 6.318

Review 2.  Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?

Authors:  Rainer Büscher; Hartmut Grasemann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-11       Impact factor: 3.000

Review 3.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

Review 4.  The heme oxygenase-carbon monoxide system: regulation and role in stress response and organ failure.

Authors:  Michael Bauer; Klaus Huse; Utz Settmacher; Ralf A Claus
Journal:  Intensive Care Med       Date:  2008-02-20       Impact factor: 17.440

5.  Increased oxidative stress induces apoptosis in human cystic fibrosis cells.

Authors:  Mathilde Rottner; Simon Tual-Chalot; H Ahmed Mostefai; Ramaroson Andriantsitohaina; Jean-Marie Freyssinet; María Carmen Martínez
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

6.  Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis.

Authors:  Hartmut Grasemann; Raphael Schwiertz; Corinna Grasemann; Udo Vester; Kurt Racké; Felix Ratjen
Journal:  Respir Res       Date:  2006-06-09

7.  Myeloperoxidase promoter polymorphism -463G is associated with more severe clinical expression of cystic fibrosis pulmonary disease.

Authors:  Wanda F Reynolds; Isabelle Sermet-Gaudelus; Valérie Gausson; Marie-Noëlle Feuillet; Jean-Paul Bonnefont; Gérard Lenoir; Béatrice Descamps-Latscha; Véronique Witko-Sarsat
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

Review 8.  CFTR activity and mitochondrial function.

Authors:  Angel Gabriel Valdivieso; Tomás A Santa-Coloma
Journal:  Redox Biol       Date:  2013-02-05       Impact factor: 11.799

9.  Genetic influences on cystic fibrosis lung disease severity.

Authors:  Colleen A Weiler; Mitchell L Drumm
Journal:  Front Pharmacol       Date:  2013-04-23       Impact factor: 5.810

10.  Application of nitric oxide measurements in clinical conditions beyond asthma.

Authors:  Andrei Malinovschi; Dora Ludviksdottir; Ellen Tufvesson; Giovanni Rolla; Leif Bjermer; Kjell Alving; Zuzana Diamant
Journal:  Eur Clin Respir J       Date:  2015-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.